| 1. |
The above audited Quarterly Results as reviewed by the Audit Committee have been taken on record by the Board at its meeting held on 02.06.2004. |
| 2. |
Investor complaints pending at the beginning of the quarter: 16, received: 211, resolved: 227 and lying unresolved at the end of the quarter: Nil. |
| 3. |
The consolidated Quarterly Results include the results of subsidiary companies and joint venture companies as per Accounting Standard 21& 27. |
| 4. |
The Board recommends dividend @45%on the equity share capital of the Company i.e Rs.2.25/- per share subject to approval of members. |
| 5. |
The Company's equity shares have been delisted from the Ahmedabad and Madras Stock Exchanges with effect from 15th January 2004 and 26th February 2004 respectively. The shares now continue to be listed on Hyderabad, Bomaby and National Stock Exchanges. |
| 6. |
Keeping in view the Company's business model of vertical integration, the management reviewed the reporting of its financial results under one segment and accordingly the Company reported its entire results under one segment viz. 'Pharmaceutical Products'. |
| 7. |
Exports (F.O.B value) constitute Rs.6420.4 Millions(Rs.5637.3 Millions) of the sales for the year. |
| 8. |
On 18th February 2004, the Company allotted 2,370,000 equity shares of Rs.5/- each to Merlion India Fund I Ltd on preferential basis and hence, the paid up capital stands increased to Rs.253.85 Million divided into 50,770,000 equity shares of Rs.5/- each. |
| 9. |
Figures have been regrouped wherever necessary. |
